Loading
Every dated change on the records linked to Pheochromocytoma and paraganglioma (PPGL), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Progression-free survival at 12 months 36 percent with sunitinib against 19 percent with placebo, meeting the primary endpoint of the first randomised trial in the disease.
Baudin and colleagues, Lancet: first randomised trial in metastatic PPGL.
Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (Azedra, high-specific-activity form; discontinued 2024)
FDA, July 2018, for unresectable MIBG-positive PPGL; later discontinued commercially.
Germline genetic testing and, for carriers, lifelong biochemical and imaging surveillance; cascade testing of relatives.
Alpha-blockade (phenoxybenzamine or doxazosin) for 7 to 14 days, volume expansion, then laparoscopic or open adrenalectomy; cortical-sparing surgery in hereditary bilateral disease.
A milestone in how this cancer is treated.